ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium
April 26, 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Corporation Announces Proposed Public Offering of Common Stock
March 17, 2021 16:01 ET
|
ContraFect Corporation
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
March 11, 2021 16:05 ET
|
ContraFect Corporation
BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim...
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update
November 13, 2020 08:33 ET
|
ContraFect Corporation
CARB-X and Cystic Fibrosis Foundation grants provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections Initiated expanded access program with exebacase for the...
ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation
August 25, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, New York, Aug. 25, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development
July 20, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
May 26, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
May 21, 2020 22:59 ET
|
ContraFect Corporation
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
May 15, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Four Abstracts Published in the 30th ECCMID Abstract Book
May 11, 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., May 11, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...